Multi-Omics Tumor Immunogenicity Score Predicts Immunotherapy Outcome and Survival
MOTIscore demonstrated improved ICI outcome predictions compared to single-omics biomarkers. Patients with higher tumor immunogenicity also show significantly improved OS and PFS in melanoma and gastric cancer. The results demonstrate the potential use of the MOTIscore to prioritize ICI in personalized cancer treatment. However, ICI outcomes and survival should be investigated in prospective studies, and additional cancer types and larger patient cohorts are needed.
Authors
- Thorben Groß (ORCID: https://orcid.org/0000-0002-7907-4373)
- Anthony W. Knapp (ORCID: https://orcid.org/0009-0005-9224-3214)
- Öznur Öner (ORCID: https://orcid.org/0000-0003-2858-3781)
- Andrea Forschner (ORCID: https://orcid.org/0000-0002-6185-4945)
- Andreas D. Hartkopf (ORCID: https://orcid.org/0000-0003-1227-1118)
- Sorin Armeanu–Ebinger
- Michael Bitzer
- Axel Gschwind (ORCID: https://orcid.org/0000-0003-1181-0335)
- Christopher Schroeder (ORCID: https://orcid.org/0000-0002-9283-3012)
- Markus Reitmajer (ORCID: https://orcid.org/0000-0002-7134-1043)
- Stephan Ossowski (ORCID: https://orcid.org/0000-0002-7416-9568)
- Ghazaleh Tabatabai (ORCID: https://orcid.org/0000-0002-3542-8782)
- A. Ott (ORCID: https://orcid.org/0009-0003-5088-2216)
- Nadja Ballin
Institutions
- Universitätsklinikum Tübingen (DE)
- Bernstein Center for Computational Neuroscience Tübingen (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Biology
- Published
- 2025-11-28
- DOI
- https://doi.org/10.3390/biology14121698
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00